NO20051023L - Oral administrering av calcitonin - Google Patents
Oral administrering av calcitoninInfo
- Publication number
- NO20051023L NO20051023L NO20051023A NO20051023A NO20051023L NO 20051023 L NO20051023 L NO 20051023L NO 20051023 A NO20051023 A NO 20051023A NO 20051023 A NO20051023 A NO 20051023A NO 20051023 L NO20051023 L NO 20051023L
- Authority
- NO
- Norway
- Prior art keywords
- calcitonin
- oral administration
- oral
- amount
- disclosed
- Prior art date
Links
- 102000055006 Calcitonin Human genes 0.000 title abstract 4
- 108060001064 Calcitonin Proteins 0.000 title abstract 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title abstract 4
- 229960004015 calcitonin Drugs 0.000 title abstract 4
- 229940124447 delivery agent Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940037448 calcitonin preparations Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40013902P | 2002-08-01 | 2002-08-01 | |
| PCT/EP2003/008498 WO2004012772A1 (en) | 2002-08-01 | 2003-07-31 | Oral administration of calcitonin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20051023L true NO20051023L (no) | 2005-04-27 |
Family
ID=31495795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20051023A NO20051023L (no) | 2002-08-01 | 2005-02-25 | Oral administrering av calcitonin |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20060135402A1 (pl) |
| EP (1) | EP1526871A1 (pl) |
| JP (4) | JP2005535689A (pl) |
| KR (6) | KR20140084354A (pl) |
| CN (1) | CN1671418A (pl) |
| AR (1) | AR040737A1 (pl) |
| AU (1) | AU2003260346B2 (pl) |
| BR (1) | BR0313177A (pl) |
| CA (1) | CA2494212A1 (pl) |
| IL (1) | IL166337A (pl) |
| MX (1) | MXPA05001266A (pl) |
| NO (1) | NO20051023L (pl) |
| NZ (1) | NZ537944A (pl) |
| PE (1) | PE20040724A1 (pl) |
| PL (1) | PL373143A1 (pl) |
| RU (1) | RU2355417C2 (pl) |
| TW (1) | TWI307279B (pl) |
| WO (1) | WO2004012772A1 (pl) |
| ZA (1) | ZA200500516B (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105641686A (zh) * | 2005-09-19 | 2016-06-08 | 爱密斯菲尔科技公司 | N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形 |
| GB0522566D0 (en) | 2005-11-04 | 2005-12-14 | Novartis Ag | Organic compounds |
| KR101564114B1 (ko) * | 2007-03-02 | 2015-10-28 | 노파르티스 아게 | 칼시토닌의 경구 투여 |
| PT2460515T (pt) * | 2007-08-09 | 2017-04-27 | Novartis Ag | Composições orais de calcitonina e suas aplicações |
| NZ585080A (en) | 2007-11-02 | 2012-05-25 | Emisphere Tech Inc | Composition comprising Vitamin B12 and N-[8-(2-hydroxybenzoyl) amino ]caprylic acid and salts thereof for treating Vitamin B12 deficiency |
| US20110039930A1 (en) * | 2009-08-03 | 2011-02-17 | Emisphere Technologies, Inc. | Fast-acting naproxen composition with reduced gastrointestinal effects |
| WO2012130193A1 (en) | 2011-03-31 | 2012-10-04 | Zentiva, K.S. | Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration |
| CN104095828A (zh) * | 2014-07-29 | 2014-10-15 | 中国药科大学 | 一种降钙素口服肠溶组合物及其制备方法 |
| CA2975676A1 (en) * | 2015-02-09 | 2016-08-18 | Entera Bio Ltd. | Formulations for oral administration of active agents with controlled absorption profile |
| CN104961687B (zh) * | 2015-06-03 | 2017-07-25 | 苏州维泰生物技术有限公司 | 1,2‑二嗪衍生物及其制剂、用途 |
| BR112023021766A2 (pt) | 2021-04-22 | 2024-01-23 | Civi Biopharma Inc | Dispensação oral de oligonucleotídeo |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629020A (en) * | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
| WO2000059480A1 (en) * | 1999-04-05 | 2000-10-12 | Emisphere Technologies, Inc. | Lyophilized solid dosage forms and methods of making |
| WO2000059863A1 (en) * | 1999-04-05 | 2000-10-12 | Emisphere Technologies, Inc. | Disodium salts, monohydrates, and ethanol solvates |
| US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
-
2003
- 2003-07-30 TW TW092120855A patent/TWI307279B/zh not_active IP Right Cessation
- 2003-07-30 AR AR20030102740A patent/AR040737A1/es unknown
- 2003-07-30 PE PE2003000747A patent/PE20040724A1/es not_active Application Discontinuation
- 2003-07-31 KR KR1020147016376A patent/KR20140084354A/ko not_active Application Discontinuation
- 2003-07-31 CA CA002494212A patent/CA2494212A1/en not_active Abandoned
- 2003-07-31 MX MXPA05001266A patent/MXPA05001266A/es unknown
- 2003-07-31 JP JP2004525407A patent/JP2005535689A/ja not_active Withdrawn
- 2003-07-31 RU RU2005105691/15A patent/RU2355417C2/ru not_active IP Right Cessation
- 2003-07-31 PL PL03373143A patent/PL373143A1/pl unknown
- 2003-07-31 AU AU2003260346A patent/AU2003260346B2/en not_active Ceased
- 2003-07-31 EP EP03766387A patent/EP1526871A1/en not_active Ceased
- 2003-07-31 CN CNA038182955A patent/CN1671418A/zh active Pending
- 2003-07-31 US US10/523,421 patent/US20060135402A1/en not_active Abandoned
- 2003-07-31 KR KR1020167025673A patent/KR20160113319A/ko not_active Application Discontinuation
- 2003-07-31 KR KR1020057001733A patent/KR20050032101A/ko not_active Application Discontinuation
- 2003-07-31 WO PCT/EP2003/008498 patent/WO2004012772A1/en active Application Filing
- 2003-07-31 NZ NZ537944A patent/NZ537944A/en not_active IP Right Cessation
- 2003-07-31 BR BR0313177-7A patent/BR0313177A/pt not_active Application Discontinuation
- 2003-07-31 KR KR1020127031292A patent/KR20130004389A/ko active Application Filing
- 2003-07-31 KR KR1020107029690A patent/KR20110014690A/ko not_active Application Discontinuation
- 2003-07-31 KR KR1020177022695A patent/KR20170097232A/ko not_active Application Discontinuation
-
2005
- 2005-01-17 IL IL166337A patent/IL166337A/en active IP Right Grant
- 2005-01-19 ZA ZA200500516A patent/ZA200500516B/xx unknown
- 2005-02-25 NO NO20051023A patent/NO20051023L/no unknown
-
2007
- 2007-05-24 US US11/805,748 patent/US7569539B2/en not_active Expired - Fee Related
-
2010
- 2010-11-08 JP JP2010249363A patent/JP2011026348A/ja active Pending
-
2013
- 2013-12-02 JP JP2013249349A patent/JP5941035B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-07 JP JP2016001745A patent/JP2016056190A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL373143A1 (pl) | 2005-08-22 |
| NZ537944A (en) | 2006-11-30 |
| JP2005535689A (ja) | 2005-11-24 |
| RU2005105691A (ru) | 2006-01-20 |
| ZA200500516B (en) | 2006-07-26 |
| WO2004012772A1 (en) | 2004-02-12 |
| EP1526871A1 (en) | 2005-05-04 |
| IL166337A (en) | 2011-10-31 |
| TW200408409A (en) | 2004-06-01 |
| KR20170097232A (ko) | 2017-08-25 |
| MXPA05001266A (es) | 2005-04-28 |
| KR20110014690A (ko) | 2011-02-11 |
| AU2003260346A1 (en) | 2004-02-23 |
| CN1671418A (zh) | 2005-09-21 |
| KR20130004389A (ko) | 2013-01-09 |
| JP2016056190A (ja) | 2016-04-21 |
| IL166337A0 (en) | 2006-01-16 |
| AR040737A1 (es) | 2005-04-20 |
| US20070232524A1 (en) | 2007-10-04 |
| KR20160113319A (ko) | 2016-09-28 |
| US7569539B2 (en) | 2009-08-04 |
| AU2003260346B2 (en) | 2007-12-13 |
| PE20040724A1 (es) | 2004-12-06 |
| KR20050032101A (ko) | 2005-04-06 |
| CA2494212A1 (en) | 2004-02-12 |
| JP2014062112A (ja) | 2014-04-10 |
| TWI307279B (en) | 2009-03-11 |
| KR20140084354A (ko) | 2014-07-04 |
| BR0313177A (pt) | 2005-06-14 |
| US20060135402A1 (en) | 2006-06-22 |
| JP2011026348A (ja) | 2011-02-10 |
| JP5941035B2 (ja) | 2016-06-29 |
| RU2355417C2 (ru) | 2009-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20051023L (no) | Oral administrering av calcitonin | |
| NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
| BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
| MXPA04004837A (es) | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. | |
| BR0109875A (pt) | Tratamento de doenças respiratórias | |
| NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
| DK1317419T3 (da) | Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler | |
| SE0001899D0 (sv) | New compounds | |
| WO2003094836A3 (en) | Methods and products for enhancing immune responses using imidazoquinoline compounds | |
| AU2003301190A1 (en) | Administration of capsaicinoids | |
| TW200607799A (en) | Therapeutic compounds: pyridine as scaffold | |
| TN2009000137A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
| BRPI0111591B8 (pt) | composto, composição farmacêutica, e, usos de um composto | |
| RS54050B1 (en) | FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS | |
| NO20024646L (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet | |
| DK1091733T3 (da) | (-)-Pseudoephedrin som et sympatomimetisk lægemiddel | |
| DK1497292T3 (da) | Azaindolylpiperidinderivater som antihistamin- og antiallergimidler | |
| RS60604A (en) | Carboxamidine derivatives and their use in the treatment of vascular diseases | |
| BR0010255A (pt) | Formulação farmacêutica, kit de partes, método para tratamento de um paciente sofrendo de ou susceptìvel a uma condição em que a inibição da trombina e/ou inibição da carboxipeptidase u são requeridas ou desejadas, e, uso de uma formulação | |
| WO2004033484A3 (en) | Use of stable glutamine derivatives to improve drug absorption | |
| BR0316123A (pt) | Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico | |
| WO2004073627A3 (en) | Novel therapeutic method and compositions for topical administration | |
| ECSP055804A (es) | Composición farmacéutica | |
| IT1320772B1 (it) | Composizione farmaceutica a base di agenti attivi contro la candidaper il trattamento di disturbi della mucosa orale e intestinale |